Although the profile is not precise enough to definitively diagnose Alzheimer’s, it offers a convenient way for doctors to determine which patients need advanced testing, according to the company.
The company now expects revenue from core business to grow in the range of 11.3%-12.6% for the year, compared with 9.5%-11% estimated earlier.
Syneos Health Inc. is making a new effort to sell itself after a reduced backlog of contracts for providing clinical research to drug developers led to a 52% plunge in its shares over the past year, according to people familiar with the matter.
However, Labcorp’s forecast is steeper than that of its closest rival Quest, which sees COVID sales declining by as much as 88% this year.
Laboratory Corp of America Holdings said it would spin off its wholly owned business focused on clinical drug trials. The planned spin-off will result in two independent, publicly traded companies – Labcorp and the clinical development business.
The Biden administration announced on Wednesday it is expanding monkeypox testing capacity to five commercial laboratory companies amid rising cases.